By Godwin Omokhagbo Emmanuel, Folahanmi Tomiwa Akinsolu , Olunike Rebecca Abodunrin,

Oliver Chukwujekwu Ezechi

ntroduction

Substance use is a growing public health concern in West Africa, contributing to significant morbidity, mortality, and socioeconomic challenges. Despite the increasing prevalence, comprehensive data on the patterns and factors influencing substance use in the region remain limited. This systematic review and meta-analysis aim to synthesize existing research on the prevalence and patterns of substance use in West Africa, providing critical insights for developing targeted interventions and policies.

Methodology

This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses [PRISMA] guidelines. A systematic search was performed across four major databases [PubMed, Web of Science, CINAHL, and Scopus] from January 2000 to June 2024. A total of 22 studies involving 43,145 participants met the inclusion criteria. Multiple reviewers performed data extraction and quality assessment independently, and a random-effects meta-analysis was used to estimate the pooled prevalence of various substances. Sensitivity analysis was conducted using a leave-one-out approach to evaluate the influence of individual studies on the overall prevalence.

Results

The meta-analysis revealed the pooled prevalence rates of alcohol [44%], cannabis [6%], tramadol [30%], codeine [11%], and kolanut [39%]. The analysis identified high heterogeneity across studies [I2 = 98– 99%], reflecting diverse substance use patterns and influencing factors, including peer influence, availability of substances, socioeconomic conditions, and demographic characteristics. Sensitivity analysis indicated that no single study significantly impacted the overall prevalence estimates, confirming the robustness of the findings.

Conclusion

Substance use in West Africa is widespread and influenced by complex factors. The high prevalence of alcohol and tramadol use highlights the urgent need for targeted public health interventions, including stricter regulatory frameworks, community-based prevention programs, and comprehensive public education campaigns. This study provides a critical foundation for developing effective strategies to mitigate the escalating substance use crisis in the region.

PLOS Glob Public Health 4(12): e0004019. https://doi.org/10.1371/journal. pgph.0004019

By Matthew F. Garnett and Arialdi M. Miniño

Drug overdoses are one of the leading causes of injury death in adults and have risen over the past several decades in the United States (1–3). Overdoses involving synthetic opioids (fentanyl, for example) and stimulants (cocaine and methamphetamine, for example) have also risen in the past few years (1). This report presents rates of drug overdose deaths from the National Vital Statistics System over a 20-year period by demographic group and by the type of drugs involved, specifically, opioids and stimulants, with a focus on changes from 2022 to 2023. Key findings Data from the National Vital Statistics System ● The age-adjusted rate of drug overdose deaths increased from 8.9deaths per 100,000 standard population in 2003 to 32.6 in 2022; however, the rate decreased to 31.3 in 2023. ● Rates decreased between 2022 and 2023 for people ages 15–54 and increased for adults age 55 and older. ● From 2022 to 2023, rates decreased for White non-Hispanic people, while rates for other race and Hispanic-origin groups generally stayed the same or increased. ● Between 2022 and 2023, rates declined for deaths involving synthetic opioids other than methadone, heroin, and natural and semisynthetic opioids, while the rate for methadone remained the same. ● From 2022 to 2023, rates increased for deaths involving cocaine by 4.9% (from 8.2 to 8.6) and psychostimulants with abuse potential by 1.9% (10.4 to 10.6)

NCHS Data Brief No. 522, December 2024. 12p.
Hyattsville, MD: National Center for Health Statistics. 2024. DOI: https://dx.doi.org/10.15620/cdc/170565.

By Tami L. Mark; Benjamin D. Huber

IMPORTANCE: Medicaid programs have expanded coverage of substance use disorder treatment and undertaken many other initiatives to reduce drug overdoses among beneficiaries. However, to date, no information has been published that tracks overdose deaths among the Medicaid population. OBJECTIVE To determine the rate of drug overdose among Medicaid beneficiaries. DESIGN, SETTING, AND PARTICIPANTS In this cross-sectional study, US Centers for Medicare & Medicaid Services data from 2016 to 2020 that linked enrollment and demographic data from all Medicaid beneficiaries in the US with the US Centers for Disease Control and Prevention National Death Index were used to determine the rate of drug overdose death among Medicaid beneficiaries. The Medicaid population rates were compared with those of the total US population, overall and by age and sex. EXPOSURE Participation in the Medicaid program. MAIN OUTCOME Death of a drug overdose. RESULTS In 2020, the drug overdose death rate among Medicaid beneficiaries was 54.6 per 100 000, a rate that was twice as high as the drug overdose rate among all US residents (27.9 per 100 000). In 2020, Medicaid beneficiaries comprised 25.0% of the US population but 48% of all overdose deaths (44 277 of 91 783). For each age and sex group older than 15 years, overdose deaths were higher for the Medicaid population than for the US population, with the greatest difference occurring among adults ages 45 to 64 years. From 2016 to 2020, Medicaid overdose deaths increased by 54%. CONCLUSIONS AND RELEVANCE The results of this study suggest that more research is needed to understand why Medicaid beneficiaries have higher rates of drug overdoses than all US residents. Additionally, research is needed to understand how best to prevent overdoses among Medicaid beneficiaries. The federal government should s

JAMA Health Forum. 2024;5(12):e244365. doi:10.1001/jamahealthforum.2024.4365

By The U.S. Drug Enforcement Administration

The most significant drug-related threat to Illinois is posed by Mexican drug trafficking organizations (DTOs), particularly the Cartel de Sinaloa (CDS) and the Cartel de Jalisco Nueva Generación (CJNG). Mexican DTOs dominate the wholesale supply of illicit opioids (fentanyl and heroin), cocaine, methamphetamine, and Mexico grown marijuana in the state.

Washington, DC: U.S. Drug Enforcement Administration, DEA Intelligence Report; 2024. 6p.

By The U.S.Drug Enforcement Administration

The most significant drug-related threat to Indiana is posed by Mexican drug trafficking organizations (DTO), particularly the Cartel de Sinaloa (CDS) and the Cartel de Jalisco Nueva Generación (CJNG). Mexican DTOs dominate the wholesale supply of illicit opioids (both fentanyl and heroin), cocaine, methamphetamine, and Mexico-grown marijuana in the state. The opioid threat remains dire and is of grave concern.

Washington, DC: U.S. Drug Enforcement Administration, DEA Intelligence Report; 2024. 7p.

By European Union Drugs Agency (EUDA).

This report explores the intricate relationship between economic recessions and illicit drug use through an in-depth scoping review of the literature. Unravelling complexities among demographics and drug types, this analysis sheds light on potential impacts of economic downturns, suggesting that young and already socioeconomically vulnerable population groups appear to be most affected during economic downturns. Among young adults, several studies indicate that the use of cannabis may increase during economic downturns. In addition, there are indications that transitioning to more problematic patterns of drug use, such as from smoking or snorting to injecting, may also increase during times of economic turmoil.

Luxembourg: Publications Office of the European Union., 2024. 60p.